8-K: Abbott Laboratories Reports Mixed Q4 and Full-Year 2023 Results, Issues 2024 Outlook

Abbott's fourth-quarter sales increased by 1.5 percent, with a significant 11.0 percent organic growth excluding COVID-19 testing sales, while full-year sales decreased by 8.1 percent due to anticipated declines in COVID-19 testing-related sales.

Summary

• Abbott Laboratories announced its fourth-quarter and full-year 2023 financial results on January 24, 2024.
• Fourth-quarter sales increased by 1.5 percent on a reported basis, 2.1 percent on an organic basis, and 11.0 percent on an organic basis excluding COVID-19 testing sales.
• Full-year 2023 reported sales decreased by 8.1 percent, primarily due to a decline in COVID-19 testing sales, but organic sales for the underlying base business increased by 11.6 percent.
• The company reported a GAAP diluted EPS of $0.91 for the fourth quarter and $3.26 for the full year, with adjusted diluted EPS of $1.19 and $4.44, respectively.
• Abbott has issued full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and adjusted diluted EPS of $4.50 to $4.70.
• The company projects full-year 2024 organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 8.0% to 10.0%.
• Abbott has regained its market-leading position in the U.S. infant formula market on a volume basis.
• The company's R&D pipeline continues to deliver new products, including the FDA approval of the GLP systems Track laboratory automation system and the first-in-human procedures using the Volt Pulsed Field Ablation System.
• Abbott's FreeStyle Libre sales were $1.4 billion in the fourth quarter, representing a 25.5 percent reported growth and 23.8 percent organic growth.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with strong underlying growth offset by the decline in COVID-19 testing revenue. The positive outlook for 2024 and the successful product launches contribute to a moderately positive sentiment.

Positives

• Abbott's underlying base business showed strong organic sales growth, increasing by 11.0% in Q4 and 11.6% for the full year, excluding COVID-19 testing sales.
• The company has successfully regained its market-leading position in the U.S. infant formula market.
• Abbott's R&D pipeline is producing new products, including the GLP systems Track and the Volt Pulsed Field Ablation System.
• FreeStyle Libre sales continue to grow significantly, reaching $1.4 billion in Q4 with a 23.8% organic growth.
• The company has issued positive guidance for 2024, projecting organic sales growth of 8.0% to 10.0% excluding COVID-19 testing sales.
• Abbott declared its 400th consecutive quarterly dividend, demonstrating a long history of shareholder returns.

Negatives

• Reported sales for the full year 2023 decreased by 8.1 percent due to the anticipated decline in COVID-19 testing-related sales.
• Diagnostics sales were negatively impacted by a significant year-over-year decline in COVID-19 testing sales.
• The company's GAAP diluted EPS for the full year 2023 was $3.26, which is lower than the adjusted diluted EPS of $4.44, indicating the impact of specified items.
• Total company sales in the US decreased by 6.4% in Q4 and 14.8% for the full year.

Risks

• The company's performance is still subject to the unpredictability of demand for COVID-19 tests.
• The company's future performance is subject to risks and uncertainties, including economic, competitive, governmental, and technological factors.
• The company's results are impacted by foreign exchange rates, which are difficult to predict.
• The company is incurring costs associated with acquisitions, restructuring, and cost reduction initiatives, which are impacting GAAP earnings.

Future Outlook

Abbott anticipates continued growth in 2024, with projected organic sales growth of 8.0% to 10.0% excluding COVID-19 testing sales and adjusted diluted EPS of $4.50 to $4.70.

Management Comments

• The strength and diversity of the Abbott portfolio drove our success in 2023, said Robert B. Ford, chairman and chief executive officer, Abbott.
• We're entering 2024 with a lot of positive momentum, and with our highly productive pipeline, we're well-positioned for growth in 2024 and beyond, said Robert B. Ford.

Industry Context

Abbott's results reflect the broader trend of declining COVID-19 testing demand, while highlighting the strength of its diversified portfolio and the success of new product launches in areas like medical devices and nutrition. The company's focus on innovation and market share recovery positions it well within the competitive healthcare landscape.

Comparison to Industry Standards

• Abbott's organic sales growth of 11.6% for the full year, excluding COVID-19 testing, is strong compared to many of its peers in the medical device and diagnostics industry, which have also faced challenges with declining COVID-19 testing revenues.
• Companies like Medtronic and Boston Scientific, which also have significant medical device businesses, have reported varying growth rates, but Abbott's performance in areas like Diabetes Care with FreeStyle Libre is particularly noteworthy.
• In the diagnostics space, companies like Roche and Siemens Healthineers have also seen a decline in COVID-19 testing revenues, making Abbott's ability to grow its base business a positive sign.
• Abbott's recovery in the infant formula market is a significant achievement, especially when compared to other players in the nutrition sector who may have faced similar supply chain challenges.

Stakeholder Impact

• Shareholders will benefit from the company's continued dividend payouts and positive growth outlook.
• Employees will be impacted by restructuring and cost reduction initiatives.
• Customers will benefit from new product launches and improved healthcare solutions.
• Suppliers will be impacted by changes in demand and supply chain dynamics.
• Creditors will be impacted by the company's financial performance and debt management.

Next Steps

• Abbott will continue to focus on its R&D pipeline and new product launches.
• The company will work to maintain its market-leading position in the U.S. infant formula market.
• Abbott will continue to monitor and manage the impact of COVID-19 testing demand on its diagnostics business.
• The company will execute its 2024 financial guidance.

Key Dates

Keywords

Abbott Laboratories, Financial Results, Organic Sales Growth, COVID-19 Testing, EPS, Medical Devices, Diagnostics, Nutrition, FreeStyle Libre, Infant Formula, Dividend, R&D, GLP systems Track, Volt Pulsed Field Ablation System